Osteoporosis - Drug Pipeline Analysis and Market Forecasts to 2016

Single User Price - US$2000
Site License Price - US$4000
Enterprisewide Price (Global Site License) - US$6000

GlobalData, the industry analysis specialist’s new report, “Osteoporosis – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global osteoporosis market. The report identifies the key trends shaping and driving the global osteoporosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global osteoporosis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global osteoporosis market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global osteoporosis market. Key players covered include Amgen, Merck & Pfizer.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with osteoporosis.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global osteoporosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global osteoporosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global osteoporosis market landscape? – Identify, understand and capitalize."

Contents

1 TABLE OF CONTENTS


1.1 LIST OF TABLES


1.2 LIST OF FIGURES


2 OSTEOPOROSIS MARKET: MARKET CHARACTERIZATION

2.1 Overview
2.2 Osteoporosis Therapeutics Market Size
2.3 Osteoporosis Therapeutics Market Forecast and CAGR
2.4 Drivers and Barriers for the Osteoporosis Therapeutics Market
  2.4.1 Drivers for the Osteoporosis Therapeutics Market
  2.4.2 Barriers for the Osteoporosis Therapeutics Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 OSTEOPOROSIS THERAPEUTICS MARKET: COMPETITIVE ASSESSMENT

3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Osteoporosis Therapeutics Market
  3.3.1 Fosamax (alendronate sodium)
  3.3.2 Actonel (risedronate sodium)
  3.3.3 Evista (raloxifene hydrochloride)
  3.3.4 Boniva (ibandronate sodium)
  3.3.5 Forteo (teriparatide [rDNA origin]) injection
3.4 Key Takeaway

4 OSTEOPOROSIS THERAPEUTICS MARKET: PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
  4.2.1 Technology Trends Analytic Framework
4.3 Osteoporosis Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
  4.4.1 Prolia (denosumab)
  4.4.2 MK-0822 (odanacatib)
  4.4.3 Viviant (bazedoxifene)
  4.4.4 PREOS (parathyroid hormone 1-84 [rDNA origin] injection)
4.5 Osteoporosis Therapeutics Market – Clinical Pipeline by Mechanism of Action
4.6 Osteoporosis Therapeutics Pipeline – Pipeline by Clinical Phases of Development
  4.6.1 Osteoporosis Therapeutics – Phase III Clinical Pipeline
  4.6.2 Osteoporosis Therapeutics – Phase II Clinical Pipeline
  4.6.3 Osteoporosis Therapeutics – Phase I Clinical Pipeline
  4.6.4 Osteoporosis Therapeutics – Pre-clinical Pipeline
  4.6.5 Osteoporosis Therapeutics – Discovery Pipeline
4.7 Key Takeaway

5 OSTEOPOROSIS THERAPEUTICS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

6 OSTEOPOROSIS THERAPEUTICS MARKET: FUTURE PLAYERS IN THE OSTEOPOROSIS THERAPEUTICS MARKET

6.1 Introduction
6.2 Amgen
  6.2.1 Overview
  6.2.2 Osteoporosis Portfolio
  6.2.3 Osteoporosis Pipeline Portfolio
6.3 Merck
  6.3.1 Overview
  6.3.2 Osteoporosis Portfolio
  6.3.3 Osteoporosis Pipeline Portfolio
6.4 Pfizer
  6.4.1 Overview
  6.4.2 Osteoporosis Portfolio
  6.4.3 Osteoporosis Pipeline Portfolio

7 OSTEOPOROSIS THERAPEUTICS MARKET: APPENDIX

7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
  7.3.1 Coverage
  7.3.2 Secondary Research
  7.3.3 Forecasting
  7.3.4 Primary Research
  7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

1.1 LIST OF TABLES

Table 1: Osteoporosis Therapeutics Market, Global, Revenues ($bn), 2001-2009
Table 2: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016
Table 3: Drugs Approved by FDA to Prevent and/or Treat Osteoporosis
Table 4: Effect of Actonel 5mg on the Risk of Vertebral Fractures
Table 5: Mean Percent Increase in BMD from Baseline in Patients Taking Actonel 5mg
Table 6: Effect of Evista on Risk of Vertebral Fractures
Table 7: Evista - (60mg Once Daily) Related Increases in BMD for the Osteoporosis Treatment vs. Placebo
Table 8: Effect of Forteo on Risk of Vertebral Fractures in Postmenopausal Women with Osteoporosis
Table 9: Mean Percent Change in BMD in Postmenopausal Women with Osteoporosis
Table 10: Major Marketed Products Comparison in the Osteoporosis Therapeutics Market, 2010
Table 11: Osteoporosis Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 12: Osteoporosis Therapeutics – Phase III Clinical Pipeline, 2010
Table 13: Osteoporosis Therapeutics – Phase II Clinical Pipeline, 2010
Table 14: Osteoporosis Therapeutics – Phase I Clinical Pipeline, 2010
Table 15: Osteoporosis Therapeutics – Pre-Clinical Pipeline, 2010
Table 16: Osteoporosis Therapeutics – Discovery Pipeline, 2010
Table 17: Amgen – Osteoporosis Pipeline Products, 2010
Table 18: Merck – Osteoporosis Pipeline Products, 2010
Table 19: Pfizer – Osteoporosis Pipeline Products, 2010

1.2 LIST OF FIGURES

Figure 1: Osteoporosis Therapeutics Market, Global, Revenues ($bn), 2001-20
09 Figure 2: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016
Figure 3: Opportunity and Unmet Need in the Osteoporosis Therapeutics Market, 2010
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Osteoporosis Therapeutics, 2010
Figure 5: Technology Trends Analytic Framework of the Osteoporosis Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Osteoporosis Therapeutics Pipeline – Description, 2010
Figure 7: Osteoporosis Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010
Figure 8: Osteoporosis Therapeutics Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in the Osteoporosis Therapeutics Market, 2010
Figure 10: Osteoporosis Therapeutics Market – Clinical Pipeline by Company (No. of Molecules), 2010
Figure 11: GlobalData Methodology
Figure 12: GlobalData Market Forecasting Model